Immunic Stock Drops 4.53%: Phase 3 Trial Enrollment Complete

Immunic, Inc. declined 4.53% in premarket trading. The company announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium, in patients with relapsing multiple sclerosis, and additional phase 2 CALLIPER trial data in patients with progressive multiple sclerosis. The data further supports the positive top-line results and underlines vidofludimus calcium’s neuroprotective potential.